Home › NDC Lookup › Ingredients › Ibuprofen › 63187-0614-30

IBU Ibuprofen 600 mg Tablet, 30-count

by Proficient Rx LP · 30 TABLET in 1 BOTTLE (63187-614-30)

NDC 63187-0614-30

🏷️ FDA NDC (as labeled) 63187-614-30 billing pads the product segment with a zero

This package

Contains30-count Pack sizes10 compare ↓

Also priced by: Part D plans $0.1000/unit — full pricing hub ↓

Also comes in: 15 tablets 63187-0614-15 20 tablets 63187-0614-20 21 tablets 63187-0614-21 28 tablets 63187-0614-28 40 tablets 63187-0614-40 42 tablets 63187-0614-42 45 tablets 63187-0614-45 60 tablets 63187-0614-60 90 tablets 63187-0614-90

Rx only Generic On market Non-controlled

🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm

📋 All sources & update times →

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️

Other active recalls for Ibuprofen (different manufacturers) — 5 · tap to view

These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.

Class II · Mar 2, 2026 — Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product. (STRIDES PHARMA INC) · FDA recall D-0390-2026

Class III · Oct 29, 2024 — Failed Tablet/Capsule Specifications (Dr. Reddy's Laboratories, Inc.) · FDA recall D-0047-2025

Class II · Aug 6, 2024 — Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit. (Dr. Reddy's Laboratories, Inc.) · FDA recall D-0644-2024

Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 63187-614-30

Product NDC 63187-614

11-digit billing NDC 63187061430

NCPDP billing unit EA — each (per item)

RxCUI 197806, 206913

UNII WK2XYI10QM

UPC 0363187614300

Application # ANDA075682

SPL Set ID a7098fa1-b5ae-485e-ada9-64154f81fb6a

Established class (EPC) Nonsteroidal Anti-inflammatory Drug

Mechanism of action Cyclooxygenase Inhibitors

Chemical class Anti-Inflammatory Agents, Non-Steroidal

DEA schedule Non-controlled

Marketing category ANDA

Marketing status On market

FDA listing status Listed (active directory)

Marketing start 2008-11-20

Route ORAL

Dosage form TABLET

Substance IBUPROFEN

GPI-14 66100020000330

GPI class Ibuprofen

GCN Seq No 008349

GCN 35742

HICL code 003723

Ingredient (HICL) Ibuprofen

HIC1 code S

Therapeutic class — broad (HIC1) Locomotor System

HIC2 code S2

Therapeutic class — intermediate (HIC2) Drugs Acting Principally On Joints

HIC3 code S2B

Therapeutic class — specific (HIC3) Nsaids, Cyclooxygenase Inhibitor Type Analgesics

AHFS code 28:08.04.04

AHFS class Reversible Cox-1/Cox-2 Inhibitors

FDB label name IBUPROFEN 600 MG TABLET

FDB brand name Ibuprofen

Legend status F — Federal legend — prescription drug or device

TE code (Orange Book) AB · RLD · RS

Why two NDCs? The FDA registers this code as 63187-614-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 63187-0614-30. Same drug, same package — only the format differs.

Where does this data come from?

Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Nonsteroidal Anti-inflammatory Drug class.

Pharmacologic class Nonsteroidal Anti-inflammatory Drug

Drug family (ATC) Other cardiac preparations, Antiinflammatory products for vaginal administration, Propionic acid derivatives

How it works Cyclooxygenase Inhibitors

Where does this data come from?

Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerProficient Rx LP

Application holderDR REDDYS LABORATORIES INC

FDA applicationANDA075682 (ANDA)

Labeler code63187

First marketedNov 2008

Product typeHuman Prescription Drug

Portfolio1,723 products on file

🔎 All NDCs from Proficient Rx LP

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).

Where does this data come from?

Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name IBUPROFEN 600 MG TABLET Ingredient Ibuprofen

📗 Our plain-language guide HelloPharmacist

It does a lot more than just kill pain. Ibuprofen is an anti-inflammatory drug, so it relieves pain, reduces swelling and inflammation, and brings down fever. Over-the-counter prod...
What's ibuprofen actually used for — is it just a painkiller?
Yes, it really does help. Ibuprofen can irritate the stomach lining, so taking it with food or a glass of milk significantly reduces the chance of nausea or stomach upset. You don'...
Should I take ibuprofen with food? Does it really matter?

📖 Read our full Ibuprofen guide →

Patient education

📘 MedlinePlus patient leaflet ↗

Supplement & herbal interactions

Some supplements/herbs that may interact with Ibuprofen — tap one for details:

Activated CharcoalMajor Coffee CharcoalModerate European MandrakeModerate GlucomannanModerate Guar GumModerate Gum ArabicModerate Slippery ElmModerate TragacanthModerate

🌿 Every supplement checked against Ibuprofen (286 interactions) — ranked by severity →

Nutrient depletion considerations

Ibuprofen may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

FOLIC ACID Insufficient Evidence

🧪 Full Ibuprofen nutrient depletion report →

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.

Where does this data come from?

Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White

ShapeCapsule

Imprint6I

Size9 mm

ScoringNot scored

One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.

Where does this data come from?

Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

UNII R12CBM0EIZ
A natural wax derived from a Brazilian palm tree, used as a coating and polish on tablets and capsules. It creates a smooth, shiny finish that protects the medicine and improves appearance.
UNII M28OL1HH48
Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
UNII 3NXW29V3WO
Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
UNII VH2XOU12IE
Polydextrose is a synthetic polymer made from dextrose (sugar) that acts as a bulking agent and filler in medicines. It helps give tablets and capsules proper volume and texture while often adding slight sweetness.
UNII 3WJQ0SDW1A
Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
UNII 6OZP39ZG8H
Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

10 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?

Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?

No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.

Why might an inactive ingredient be missing?

Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.

Can inactive ingredients matter?

Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price system	Per each	Per package
Retail pharmacies payNADAC · weekly	Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo	No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026	$0.1000	$3.00 / 30 tablets

Where does this data come from?

NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

Product	Labeler	Pack	NADAC/unit	TE	Status	Price vs. this
Ibuprofen 600 mg 42543-0965-07	Strides	500 tablets	$0.044	AB	Discontinued	—
Ibuprofen 600 mg 00904-5854-40	Major	500 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 00904-7588-40	Major	500 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 49483-0603-01	TIME	100 tablets	$0.047	AB	Availability likely	—
Ibu 600 mg 55111-0683-01	Dr.	100 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 59651-0361-01	Aurobindo	100 tablets	$0.047	—	Availability likely	—
Ibuprofen 600 mg 60687-0457-01	American	100 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 62135-0401-12	Chartwell	120 tablets	$0.047	—	Availability likely	—
Ibuprofen 600 mg 64380-0808-06	Strides	100 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 67877-0320-01	Ascend	100 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 68645-0562-59	Legacy	60 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 69367-0395-01	Westminster	100 tablets	$0.047	—	Availability likely	—
Ibuprofen 600 mg 76282-0713-10	EXELAN	100 tablets	$0.047	AB	Availability likely	—
Ibuprofen 600 mg 71921-0181-01	Florida	100 tablets	$0.052	AB	FDA listed	—
Ibuprofen 600 mg 69238-1102-05	Amneal	500 tablets	$0.059	AB	FDA listed	—
Ibuprofen 600 mg 00615-8310-39	NCS	30 tablets	—	AB	Discontinued	—
Ibuprofen 600 mg 11788-0009-00	AiPing	22600 tablets	—	—	Discontinued	—
Ibuprofen 600 mg 25000-0122-03	MARKSANS	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 42708-0097-30	QPharma,	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 42708-0175-30	QPharma	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 43063-0867-01	PD-Rx	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 50090-2625-00	A-S	10 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 50090-2626-00	A-S	15 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 50090-2629-00	A-S	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 50090-5433-01	A-S	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 50090-5435-00	A-S	10 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 50090-7286-00	A-S	15 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 50090-7288-00	A-S	10 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 50090-7321-00	A-S	30 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 51407-0840-01	Golden	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 51655-0042-20	Northwind	20 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 51655-0474-20	Northwind	20 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 53746-0132-01	Amneal	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 53746-0465-01	Amneal	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 54348-0830-00	PharmPak,	1 tablet	—	AB	FDA listed	—
Ibuprofen 600 mg 55154-0741-00	Cardinal	1 tablet	—	AB	FDA listed	—
Ibupak 59088-0756-00	PureTek	100 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 60760-0597-20	ST.	20 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 60760-0603-20	St.	20 tablets	—	AB	Discontinued	—
Ibuprofen 600 mg 62207-0355-42	Granules	50 tablets	—	AB	FDA listed	—
ibuprofen 600 mg 63187-0451-30	Proficient	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 63187-0527-20	Proficient	20 tablets	—	AB	FDA listed	—
Ibu 600 mgthis 63187-0614-30	Proficient	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 63187-0980-15	Proficient	15 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 65162-0465-03	Amneal	30 tablets	—	AB	FDA listed	—
Ibu 600 mg 66267-0964-00	NuCare	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 67046-1646-03	Coupler	30 tablets	—	—	FDA listed	—
Ibu 600 mg 67296-0913-01	RedPharm	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 67296-2181-01	Redpharm	10 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 68071-2947-01	NuCare	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-2998-06	NuCare	6 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-3679-01	NuCare	100 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 68071-3778-02	NuCare	20 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 68071-3849-04	NuCare	4 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 68071-4009-01	NuCare	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-4243-01	NuCare	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-4459-06	NuCare	6 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-4887-03	NuCare	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-4968-03	NuCare	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68071-5066-04	NuCare	4 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68788-8354-01	Preferred	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68788-8531-01	Preferred	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68788-8754-01	Preferred	100 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 68788-9111-01	Preferred	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 69367-0448-01	Westminster	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 70010-0067-88	Granules	15000 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 70518-0761-00	REMEDYREPACK	20 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 70518-1364-01	REMEDYREPACK	30 tablets	—	AB	Discontinued	—
Ibuprofen 600 mg 70518-2902-00	REMEDYREPACK	30 tablets	—	—	Discontinued	—
Ibuprofen 600 mg 70518-3313-00	REMEDYREPACK	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 70518-4341-00	REMEDYREPACK	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71205-0522-06	Proficient	6 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71335-1207-00	Bryant	21 tablets	—	AB	Discontinued	—
Ibuprofen 600 mg 71335-1218-00	Bryant	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71335-1503-00	Bryant	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71335-2683-00	Bryant	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71335-3121-00	Bryant	21 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 71610-0222-60	Aphena	90 tablets	—	AB	FDA listed	—
Ibu 600 mg 71610-0501-60	Aphena	90 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71610-0532-60	Aphena	90 tablets	—	AB	FDA listed	—
Ibu 600 mg 71610-0547-60	Aphena	90 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71610-0629-60	Aphena	90 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71610-0891-53	Aphena	60 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71610-0895-60	Aphena	90 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 71610-0902-53	Aphena	60 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 71610-0968-53	Aphena	60 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 72189-0231-21	DIRECT	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 72189-0643-21	Direct_Rx	21 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 72603-0909-01	NorthStar	500 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 72789-0187-30	PD-Rx	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 72789-0212-06	PD-Rx	6 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 72789-0363-01	PD-Rx	100 tablets	—	AB	FDA listed	—
ibuprofen 600 mg 73086-0211-01	SKYA	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 75907-0330-91	Dr.	2000 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 76420-0576-01	Asclemed	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 76420-0847-01	Asclemed	100 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 80425-0132-01	Advanced	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 80425-0154-01	Advanced	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 80425-0424-01	Advanced	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 80425-0426-01	Advanced	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 80425-0553-01	Advanced	30 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 83008-0066-30	Quality	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 83615-0001-03	Bryant	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 87441-0044-01	Unit	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 85766-0219-01	Sportpharm	100 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 85534-0012-00	HAWAII	30 tablets	—	AB	FDA listed	—
Ibuprofen 600 mg 68788-4140-01	Preferred	100 tablets	—	—	FDA listed	—
Ibuprofen 600 mg 70518-4741-00	REMEDYREPACK	1 tablet	—	AB	FDA listed	—
Ibuprofen 600 mg 67877-0738-01	Ascend	100 tablets	—	AB	FDA listed	—

About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.

Where does this data come from?

Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️

2008

On the market since

Nov 2008

📍

2026

Currently FDA-listed

18 years listed

🔓

Generic on the market

this product is a generic

✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?

Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ibu — the program that covers self-administered drugs. 1 manufacturer.

⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ibu. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.

Period

Total Part D spend

$322.2K

Claims incl. refills

63.5K

Beneficiaries

50.9K

Spend / beneficiary

$6.33

Spend / claim

$5.07

Trend by period

💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDC	Description	Marketing start	Status
63187-0614-15	15 TABLET in 1 BOTTLE (63187-614-15)	2016-01-01	Active
63187-0614-20	20 TABLET in 1 BOTTLE (63187-614-20)	2017-03-01	Active
63187-0614-28	28 TABLET in 1 BOTTLE (63187-614-28)	2019-10-01	Active
63187-0614-30 You're viewing this	30 TABLET in 1 BOTTLE (63187-614-30)	2016-01-01	Active
63187-0614-40	40 TABLET in 1 BOTTLE (63187-614-40)	2017-06-01	Active
63187-0614-42	42 TABLET in 1 BOTTLE (63187-614-42)	2020-02-21	Active
63187-0614-45	45 TABLET in 1 BOTTLE (63187-614-45)	2016-01-01	Active
63187-0614-60	60 TABLET in 1 BOTTLE (63187-614-60)	2016-01-01	Active
63187-0614-90	90 TABLET in 1 BOTTLE (63187-614-90)	2016-01-01	Active
63187-0614-21	21 TABLET in 1 BOTTLE (63187-614-21)	2025-12-11	Active

You're viewing one of 10 pack sizes for this product.

Pack size FAQ

What quantity is in NDC 63187-0614-30?

NDC 63187-0614-30 is a 30-count package — 30 tablet in 1 bottle.

What is the difference between NDC 63187-0614-30 and NDC 63187-0614-15?

Both are IBU Ibuprofen 600 mg Tablet — the drug itself is identical. NDC 63187-0614-30 is the 30-count package, while NDC 63187-0614-15 is the 15 tablets package.

What NDC number is used to bill for this package of IBU Ibuprofen 600 mg Tablet?

Bill NDC 63187-0614-30 — the 11-digit billing format is 63187061430. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

🧭 About this NDC listing & data coverage

Finished prescription product

What data is (and isn’t) available for this NDC — tap to expand

NDC identity (package / product / labeler codes)	✓ Available
Labeler	✓ Available
Product & package description	✓ Available
Marketing category & status	✓ Available
Active ingredient / dosage form / route	✓ Available
FDA label (SPL via DailyMed)	✓ Available
Package photos	✓ Available
Inactive ingredients (structured)	✓ Available
NADAC pharmacy acquisition price (CMS)	— Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data	✓ Available
HCPCS J-code billing crosswalk	— Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD)	— Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.

“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?

The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.

Is the NDC printed on the package the same as the 11-digit billing NDC?

Yes, they identify this exact package in different formats. The FDA registers it as 63187-614-30, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 63187-0614-30, written without dashes as 63187061430. The Identity section at the top of this page lists every form of this code.

What do the three segments of this NDC mean?

In 63187-0614-30, the first segment (63187) is the labeler code FDA assigned to Proficient Rx LP; the middle segment (0614) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (30) identifies this exact package size and type. Together they name one specific package of one specific product.

Is this package still being marketed?

Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Proficient Rx LP. Listing status can change — the directory data on this page refreshes weekly.

Does this product come in other package sizes?

Yes — the FDA directory lists 9 other package presentations of this same product, including 15 tablets (63187-0614-15), 20 tablets (63187-0614-20), 21 tablets (63187-0614-21). Each has its own NDC and its own page — see the package list near the top of this page.

Who lists this product with the FDA?

Proficient Rx LP is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.

Do I need a prescription for this product?

This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.

This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.

Where does this data come from?

Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.

🚨 Boxed Warning 🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients

🚨 Boxed Warning 115 words ▾

BOXED WARNING Cardiovascular Risk 1. NSAIDs may cause an increased risk of serious cardiovascularthrombotic events, myocardial infarction, and stroke,which can be fatal. This risk may increase with duration ofuse.

Patients with cardiovascular disease or risk factors forcardiovascular disease may be at greater risk (See WARNINGS ). 2. IBU tablets are contraindicated for treatment of peri-operativepain in the setting of coronary artery bypass graft (CABG)surgery (See WARNINGS ).

Gastrointestinal Risk 1. NSAIDS cause an increased risk of serious gastrointestinaladverse events including bleeding, ulceration, and perforationof the stomach or intestines, which can be fatal. These eventscan occur at any time during use and without warning symptoms.Elderly patients are at greater risk for serious gastrointestinalevents.

(See WARNINGS ).

🎯 Indications and Usage 93 words ▾

INDICATIONS AND USAGE Carefully consider the potential benefits and risks of Ibuprofentablets and other treatment options before deciding to use Ibuprofen.Use the lowest effective dose for the shortest duration consistent withindividual patient treatment goals (see WARNINGS ). IBU tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. IBU tablets are indicated for relief of mild to moderate pain.

IBU tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of IBU tablets in children have not been conducted.

⏱️ Dosage and Administration ~2 min read ▾

DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of IBU tabletsand other treatment options before deciding to use IBU tablets. Usethe lowest effective dose for the shortest duration consistent withindividual patient treatment goals (see WARNINGS). After observing the response to initial therapy with IBU tablets, thedose and frequency should be adjusted to suit an individual patient’sneeds.Do not exceed 3200 mg total daily dose.

If gastrointestinal complaintsoccur, administer IBU tablets with meals or milk. Rheumatoid arthritis and osteoarthritis, including flare-ups ofchronic disease: Suggested Dosage: 1200 mg-3200 mg daily (400 mg, 600 mg or800 mg tid or qid). Individual patients may show a better responseto 3200 mg daily, as compared with 2400 mg, although in well-controlledclinical trials patients on 3200 mg did not show a better meanresponse in terms of efficacy.

Therefore, when treating patients with3200 mg/day, the physician should observe sufficient increased clinicalbenefits to offset potential increased risk.The dose should be tailored to each patient, and may be loweredor raised depending on the severity of symptoms either at time of initiatingdrug therapy or as the patient responds or fails to respond.In general, patients with rheumatoid arthritis seem to require higherdoses of IBU tablets than do patients with osteoarthritis. The smallest dose of IBU tablets that yields acceptable controlshould be employed.

A linear blood level dose-response relationshipexists with single doses up to 800 mg (See CLINICAL PHARMACOLOGYfor effects of food on rate of absorption). The availability of three tablet strengths facilitates dosage adjustment.In chronic conditions, a therapeutic response to therapy with IBU tablets is sometimes seen in a few days to a week but most often isobserved by two weeks. After a satisfactory response has beenachieved, the patient’s dose should be reviewed and adjusted asrequired.

Mild to moderate pain: 400 mg every 4 to 6 hours as necessaryfor relief of pain.In controlled analgesic clinical trials, doses of Ibuprofen tabletsgreater than 400 mg were no more effective than the 400 mg dose. Dysmenorrhea: For the treatment of dysmenorrhea, beginningwith the earliest onset of such pain, IBU tablets should be given in adose of 400 mg every 4 hours as necessary for the relief of pain.

⛔ Contraindications 76 words ▾

CONTRAINDICATIONS IBU tablets are contraindicated in patients with known hypersensitivityto ibuprofen. IBU tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin orother NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS, Anaphylactoid Reactions, and PRECAUTIONS, Preexisting Asthma ).

IBU tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery(see WARNINGS ).

⚠️ Warnings ~3 min read ▾

WARNINGS CARDIOVASCULAR EFFECTS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDsof up to three years duration have shown an increased risk of seriouscardiovascular (CV) thrombotic events, myocardial infarction, andstroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective,may have a similar risk. Patients with known CV disease orrisk factors for CV disease may be at greater risk.

To minimize thepotential risk for an adverse CV event in patients treated with anNSAID, the lowest effective dose should be used for the shortestduration possible. Physicians and patients should remain alert for thedevelopment of such events, even in the absence of previous CVsymptoms. Patients should be informed about the signs and/orsymptoms of serious CV events and the steps to take if they occur.

There is no consistent evidence that concurrent use of aspirin mitigatesthe increased risk of serious CV thrombotic events associatedwith NSAID use. The concurrent use of aspirin and an NSAID doesincrease the risk of serious GI events (see GI WARNINGS) . Two large, controlled clinical trials of a COX-2 selective NSAID forthe treatment of pain in the first 10-14 days following CABG surgeryfound an increased incidence of myocardial infarction and stroke (see CONTRAINDICATIONS ).

Hypertension NSAIDs including IBU tablets, can lead to onset of new hypertensionor worsening of preexisting hypertension, either of which maycontribute to the increased incidence of CV events. Patients takingthiazides or loop diuretics may have impaired response to these therapieswhen taking NSAIDs. NSAIDs, including IBU tablets, should beused with caution in patients with hypertension.

Blood pressure (BP)should be monitored closely during the initiation of NSAID treatmentand throughout the course of therapy. Congestive Heart Failure and Edema Fluid retention and edema have been observed in some patients taking NSAIDs. IBU tablets should be used with caution in patients with fluid retention or heart failure.

Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation NSAIDs, including IBU tablets, can cause serious gastrointestinal(GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic.

Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patientstreated for 3-6 months, and in about 2-4% of patients treated for oneyear. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.

NSAIDs should be prescribed with extreme caution in thosewith a prior history of ulcer disease or gastrointestinal bleeding.Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients treatedwith neither of these risk factors. Other factors that increase the riskof GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status.

Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GIulcerations and bleeding during NSA…

🤒 Adverse Reactions 202 words ▾

ADVERSE REACTIONS The most frequent type of adverse reaction occurring withIbuprofen tablets is gastrointestinal. In controlled clinical trials thepercentage of patients reporting one or more gastrointestinal complaintsranged from 4% to 16%. In controlled studies when Ibuprofen tablets were compared toaspirin and indomethacin in equally effective doses, the overall incidenceof gastrointestinal complaints was about half that seen in eitherthe aspirin- or indomethacin-treated patients.

Adverse reactions observed during controlled clinical trials at anincidence greater than 1% are listed in the table. Those reactions listedin Column one encompass observations in approximately 3,000patients. More than 500 of these patients were treated for periods ofat least 54 weeks.

Still other reactions occurring less frequently than 1 in 100 werereported in controlled clinical trials and from marketing experience.These reactions have been divided into two categories: Column twoof the table lists reactions with therapy with Ibuprofen tablets wherethe probability of a causal relationship exists: for the reactions inColumn three, a causal relationship with Ibuprofen tablets has notbeen established. Reported side effects were higher at doses of 3200 mg/day thanat doses of 2400 mg or less per day in clinical trials of patients withrheumatoid arthritis.

The increases in incidence were slight and stillwithin the ranges reported in the table. table

🔄 Drug Interactions 75 words ▾

Drug Interactions ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensiveeffect of ACE-inhibitors. This interaction should be given considerationin patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When IBU tablets are administered with aspirin, its protein bindingis reduced, although the clearance of free IBU tablets is notaltered.

The clinical significance of this interaction is not known; however,as with other NSAIDs, concomitant administration of ibuprofenand aspirin is not generally recommended because of the potential forincreased adverse effects.

🤰 Pregnancy ~1 min read ▾

Pregnancy In late pregnancy, as with other NSAIDs, IBU tablets should beavoided because it may cause premature closure of the ductus arteriosus.

Ophthalmological effects. Blurred and/or diminished vision, scotomata, and/or changes incolor vision have been reported. If a patient develops such complaintswhile receiving IBU tablets, the drug should be discontinued, and thepatient should have an ophthalmologic examination which includescentral visual fields and color vision testing.

Pregnancy Teratogenic effects: Pregnancy Category C Reproductive studies conducted in rats and rabbits have notdemonstrated evidence of developmental abnormalities. However,animal reproduction studies are not always predictive of humanresponse. There are no adequate and well-controlled studies in pregnantwomen.

Ibuprofen should be used in pregnancy only if thepotential benefit justifies the potential risk to the fetus. Nonteratogenic effects Because of the known effects of NSAIDs on the fetal cardiovascularsystem (closure of ductus arteriosus), use during late pregnancyshould be avoided. Labor and Delivery In rat studies with NSAIDs, as with other drugs known to inhibitprostaglandin synthesis, an increased incidence of dystocia, delayedparturition, and decreased pup survival occurred.

The effects of IBUtablets on labor and delivery in pregnant women are unknown. Nursing Mothers It is not known whether this drug is excreted in human milk.Because many drugs are excreted in human-milk and because of thepotential for serious adverse reactions in nursing infants from IBUtablets, a decision should be made whether to discontinue nursing ordiscontinue the drug, taking into account the importance of the drugto the mother. Pediatric Use Safety and effectiveness of IBU tablets in pediatric patients havenot been established.

Geriatric Use As with any NSAIDs, caution should be exercised in treating theelderly (65 years and older).

🆘 Overdosage ~1 min read ▾

OVERDOSAGE Approximately 11⁄2 hours after the reported ingestion of from 7 to10 Ibuprofen tablets (400 mg), a 19-month old child weighing 12 kgwas seen in the hospital emergency room, apneic and cyanotic,responding only to painful stimuli. This type of stimulus, however,was sufficient to induce respiration. Oxygen and parenteral fluidswere given; a greenish-yellow fluid was aspirated from the stomachwith no evidence to indicate the presence of ibuprofen.

Two hoursafter ingestion the child’s condition seemed stable; she still respondedonly to painful stimuli and continued to have periods of apnea lastingfrom 5 to 10 seconds. She was admitted to intensive care andsodium bicarbonate was administered as well as infusions of dextroseand normal saline. By four hours post-ingestion she could bearoused easily, sit by herself and respond to spoken commands.Blood level of ibuprofen was 102.9 μg/mL approximately 81⁄2 hoursafter accidental ingestion.

At 12 hours she appeared to be completelyrecovered. In two other reported cases where children (each weighingapproximately 10 kg) accidentally, acutely ingested approximately120 mg/kg, there were no signs of acute intoxication or late sequelae.Blood level in one child 90 minutes after ingestion was 700 μg/mL —about 10 times the peak levels seen in absorption-excretion studies.A 19-year old male who had taken 8,000 mg of ibuprofen over aperiod of a few hours complained of dizziness, and nystagmus wasnoted. After hospitalization, parenteral hydration and three days bedrest, he recovered with no reported sequelae.

In cases of acute overdosage, the stomach should be emptied byvomiting or lavage, though little drug will likely be recovered if morethan an hour has elapsed since ingestion. Because the drug is acidicand is excreted in the urine, it is theoretically beneficial to administeralkali and induce diuresis. In addition to supportive measures, the useof oral activated charcoal may help to reduce the absorption andreabsorption of Ibuprofen tablets.

🧬 Clinical Pharmacology ~3 min read ▾

CLINICAL PHARMACOLOGY IBU tablets contain ibuprofen which possesses analgesic andantipyretic activities. Its mode of action, like that of other NSAIDs, isnot completely understood, but may be related to prostaglandin synthetaseinhibition. In clinical studies in patients with rheumatoid arthritis andosteoarthritis, Ibuprofen tablets have been shown to be comparableto aspirin in controlling pain and inflammation and to be associatedwith a statistically significant reduction in the milder gastrointestinalside effects (see ADVERSE REACTIONS ).

Ibuprofen may be well tolerated in some patients who have had gastrointestinal side effects with aspirin, but these patients when treated with IBU tablets should be carefully followed for signs and symptoms of gastrointestinal ulceration and bleeding. Although it is not definitely known whether ibuprofen causes less peptic ulceration than aspirin, in one study involving 885 patients with rheumatoid arthritis treated for up to one year, there were no reports of gastric ulceration with ibuprofen whereas frank ulceration was reported in 13 patients in the aspirin group (statistically significant p<.001).

Gastroscopic studies at varying doses show an increased tendency toward gastric irritation at higher doses. However, at comparable doses, gastric irritation is approximately half that seen with aspirin. Studies using 51Cr-tagged red cells indicate that fecal blood loss associated with Ibuprofen tablets in doses up to 2400 mg daily did not exceed the normal range, and was significantly less than that seen in aspirin-treated patients.

In clinical studies in patients with rheumatoid arthritis, Ibuprofen has been shown to be comparable to indomethacin in controlling the signs and symptoms of disease activity and to be associated with a statistically significant reduction of the milder gastrointestinal (see ADVERSE REACTIONS ) and CNS side effects. Ibuprofen may be used in combination with gold salts and/or corticosteroids. Controlled studies have demonstrated that Ibuprofen is a more effective analgesic than propoxyphene for the relief of episiotomy pain, pain following dental extraction procedures, and for the relief of the symptoms of primary dysmenorrhea.

In patients with primary dysmenorrhea, Ibuprofen has been shown to reduce elevated levels of prostaglandin activity in the menstrual fluid and to reduce resting and active intrauterine pressure, as well as the frequency of uterine contractions. The probable mechanism ofaction is to inhibit prostaglandin synthesis rather than simply to provide analgesia. The ibuprofen in IBU tablets is rapidly absorbed.

Peak serum ibuprofen levels are generally attained one to two hours after administration. With single doses up to 800 mg, a linear relationship exists between amount of drug administered and the integrated area under the serum drug concentration vs time curve. Above 800 mg, however, the area under the curve increases less than proportional to increases in dose.

There is no evidence of drug accumulation or enzyme induction. The administration of Ibuprofen tablets either under fasting conditions or immediately before meals yields quite similar serum ibuprofen concentration-time profiles. When Ibuprofen is administered immediately after a meal, there is a reduction in the rate of absorption but no appreciable decrease in the extent of absorption.

The bioavailability of the drug is minimally altered by the presence of food. A bioavailability study has shown that there was no interference with the absorption of ibuprofen when given in conjunction with anantacid containing both aluminum hydroxide and magnesium hydroxide. Ibuprofen is rapidly metabolized and eliminated in the urine.

The excretion of ibuprofen is virtually complete 24 hours after the last dose. The serum half-life is 1.8 to 2.0 hours. Studies have shown that following ingestion of the drug, 45% to79% of the dose was recovered in the urine within 24 hours as metabolite A (25%), (+)-2-[ p…

📦 How Supplied / Storage and Handling 101 words ▾

HOW SUPPLIED IBU tablets are available in the following strengths, colors and sizes: 600 mg (white, caplet, debossed 6I) Bottles of 15 NDC 63187-614-15 Bottles of 20 NDC 63187-614-20 Bottles of 21 NDC 63187-614-21 Bottles of 28 NDC 63187-614-28 Bottles of 30 NDC 63187-614-30 Bottles of 40 NDC 63187-614-40 Bottles of 42 NDC 63187-614-42 Bottles of 45 NDC 63187-614-45 Bottles of 60 NDC 63187-614-60 Bottles of 90 NDC 63187-614-90 Store at room temperature. Avoid excessive heat 40°C (104°F). Manufactured by: Dr.

Reddy’s Laboratories Louisiana, LLC Shreveport, LA 71106 USA Revised, October 2013 Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320

📋 Description 92 words ▾

DESCRIPTION IBU tablets contain the active ingredient ibuprofen, which is (±) -2 - ( p - isobutylphenyl) propionic acid. Ibuprofen is a white powde rwith a melting point of 74-77° C and is very slightly soluble in water(<1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula is represented below: IBU, a nonsteroidal anti-inflammatory drug (NSAID), is availablein 400 mg, 600 mg, and 800 mg tablets for oral administration.Inactive ingredients: carnauba wax, colloidal silicon dioxide,croscarmellose sodium, hypromellose, magnesium stearate, microcrystallinecellulose, polydextrose, polyethylene glycol, polysorbate,titanium dioxide. strucuture

💬 Information for Patients ~2 min read ▾

Information for Patients Patients should be informed of the following information beforeinitiating therapy with an NSAID and periodically during the course ofongoing therapy. Patients should also be encouraged to read theNSAID Medication Guide that accompanies each prescription dispensed • IBU tablets like other NSAIDs, may cause serious CV side effects,such as MI or stroke, which may result in hospitalization and evendeath. Although serious CV events can occur without warningsymptoms, patients should be alert for the signs and symptoms ofchest pain, shortness of breath, weakness, slurring of speech, andshould ask for medical advice when observing any indicative sign orsymptoms.

Patients should be apprised of the importance of thisfollow-up (see WARNINGS, Cardiovascular Effects ). • IBU tablets, like other NSAIDs, can cause GI discomfort and, rarely,serious GI side effects, such as ulcers and bleeding, which mayresult in hospitalization and even death. Although serious GI tractulcerations and bleeding can occur without warning symptoms,patients should be alert for the signs and symptoms of ulcerationsand bleeding, and should ask for medical advice when observingany indicative signs or symptoms including epigastric pain, dyspepsia,melena, and hematemesis.

Patients should be apprised of theimportance of this follow-up (see WARNINGS, Gastrointestinal Effects-Risk of Ulceration , Bleeding and Perforation) . • IBU tablets, like other NSAIDs, can cause serious skin side effectssuch as exfoliative dermatitis, SJS and TEN, which may result inhospitalization and even death. Although serious skin reactions mayoccur without warning, patients should be alert for the signs andsymptoms of skin rash and blisters, fever, or other signs of hypersensitivitysuch as itching, and should ask for medical advice whenobserving any indicative sign or symptoms.

Patients should beadvised to stop the drug immediately if they develop any type ofrash and contact their physicians as soon as possible. • Patients should promptly report signs or symptoms of unexplainedweight gain or edema to their physicians. • Patients should be informed of the warning signs and symptoms ofhepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice,right upper quadrant tenderness and “flu-like” symptoms). If theseoccur, patients should be instructed to stop therapy and seek immediatemedical therapy. • Patients should be informed of the signs of an anaphylactoid reaction(e.g. difficulty breathing, swelling of the face or throat).

If theseoccur, patients should be instructed to seek immediate emergencyhelp (see WARNINGS) . • In late pregnancy, as with other NSAIDs, IBU tablets should beavoided because it may cause premature closure of the ductus arteriosus.

Glossary — plain-language definitions of medical terms used in this label:

contraindicated: Should not be used in that situation, because the risk is considered too high.

Absorption: How a medicine moves from where it is taken, such as the stomach or gut, into the bloodstream.

accumulation: A buildup of a medicine in the body when new doses are taken before earlier ones are fully removed.

Active ingredient: The part of a medicine that produces its intended effect on the body.

adverse event: Any unwanted medical problem that happens during treatment, whether or not the medicine actually caused it.

adverse reaction: An unwanted or harmful effect that a medicine causes in the body.

Adverse Reactions: Unwanted or harmful effects that people experienced while taking a medicine, listed on its official label.

anaphylactoid reaction: A severe reaction that looks like a serious allergic reaction but is not caused by the usual allergy antibodies.

animal reproduction studies: Tests in pregnant animals used to check whether a medicine might harm a developing baby.

apnea: A pause or temporary stop in breathing.

Bioavailability: The share of a dose that actually reaches the bloodstream and is able to have an effect.

Boxed Warning: The strongest safety warning the FDA can require, set inside a bold black border because the risk it describes can be very serious.

clearance: How quickly the body removes a medicine from the blood, usually through the liver and kidneys.

Clinical Pharmacology: The label section explaining how a medicine works in the body and how the body processes it.

Clinical Studies: The label section summarizing the research trials used to show that a medicine works and is acceptably safe.

Contraindications: A list of situations or health conditions in which a medicine should not be used because the chance of harm is too high.

dermatitis: Inflammation of the skin, causing redness, itching, and sometimes swelling or blisters.

Dosage and Administration: The label section explaining how much of a medicine to use and how to take or give it.

dose-response: The relationship between the size of a dose and the strength of the body's reaction to it.

Drug Interactions: The label section listing other medicines, foods, or substances that can change how a medicine works or raise the chance of side effects.

dyspepsia: Discomfort, fullness, or a burning feeling in the upper belly, commonly called indigestion.

edema: Swelling caused by extra fluid trapped in the body's tissues.

efficacy: How well a treatment works under the controlled conditions of a clinical study.

enzyme induction: When a substance makes the body produce more of an enzyme, speeding up how fast certain drugs are removed.

Excretion: How the body removes a medicine or its leftover pieces, mainly through the urine or stool.

exfoliative dermatitis: Widespread redness with heavy scaling or peeling of the skin over most of the body.

gastrointestinal bleeding: Bleeding anywhere along the digestive tract, from the food pipe down to the bowel.

Half-life: The time it takes for the amount of medicine in the blood to drop by half.

heart failure: A condition in which the heart cannot pump blood as well as it should, causing tiredness, breathlessness, and swelling.

hematemesis: Vomiting blood, which may look bright red or like dark coffee grounds.

hypertension: Blood pressure that stays higher than normal, commonly called high blood pressure.

incidence: How often a new event, such as a side effect, happens in a group of people over a set period of time.

Indications and Usage: The label section stating which medical conditions the FDA has officially approved the medicine to treat, prevent, or manage.

jaundice: Yellowing of the skin and the whites of the eyes caused by too much bilirubin in the blood.

lethargy: A state of tiredness and sluggishness, often with slowed thinking or movement.

Medication Guide: An FDA-approved handout written for patients that explains important safety information about certain medicines in plain language.

melena: Black, sticky, tar-like stools caused by blood that has been digested higher up in the gut.

metabolite: A new substance formed when the body breaks a medicine down.

myocardial infarction: The medical term for a heart attack, when blood flow to part of the heart muscle is blocked.

NDC: A unique number that identifies a specific medicine, its maker, strength, and package size.

nystagmus: Rapid, involuntary back-and-forth movements of the eyes that a person cannot control.

Overdosage: The label section describing what can happen if too much of a medicine is taken and how it may be treated.

parenteral: Given by injection or drip into the body rather than swallowed by mouth.

perforation: A hole that forms all the way through the wall of the stomach or intestine.

pregnancy category: An older letter rating (A, B, C, D, or X) once used to describe a medicine's possible risk during pregnancy.

pruritus: Itching of the skin.

statistically significant: A result unlikely to be due to chance alone, suggesting a real difference between the groups being compared.

teratogenic: Able to cause physical birth defects in a developing baby when a medicine is taken during pregnancy.

ulceration: The forming of an open sore on the skin or on a lining inside the body, such as the stomach.

urticaria: Raised, itchy welts on the skin, commonly called hives.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

← 63187-0612-30 · Proficient 63187-0616-00 · Proficient →

For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.

IBU Ibuprofen 600 mg Tablet, 30-count

🆔 Identity & classification

🏷️ RxNorm drug class

🏭 Manufacturer & labeler

🩺 Clinical

Patient education

Supplement & herbal interactions

💊 What it looks like

🧪 Inactive Ingredients / Excipients

Inactive ingredient FAQ

💲 Pricing

🔁 Therapeutic equivalents

⏳ Availability & generic status

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

📦 Packaging — all sizes for this product

Pack size FAQ

🧭 About this NDC listing & data coverage

Questions about this listing

📄 Full prescribing information FDA SPL

🔗 Related NDC lookups

💊 Related drugs in this class